AUG 0 9 2007

PTC/SB/26 (04-07)
Approved for use through 09/30/2007, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING **REJECTION OVER A "PRIOR" PATENT**

Docket Number (Optional) 61011-016002

In re Application of: Qingbo Li, et al.
Application No.: 10/679,514
Filed: October 7, 2003
For: Uniform Laser Excitation and Detection in Capillary Arrayelectrophoresis Sylem and Method
The owner*, SpectruMedix LLC , of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term prior patent No. 6,630,063 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:  expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is relssued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.
Check either box 1 or 2 below, if appropriate.
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.
2. The undersigned is an attorney or agent of record. Reg. No
July 13, 2007
Signature Date
John Ritson, President & CEO, SpectruMedix LLC
Typed or printed name
(814) 404-5263 Telephone Number
Terminal disclaimer fee under 37 CFR 1.20(d) included.
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.
This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO

to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

AUG 0 9 2007 W

PTO/S8/95 (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner: SpectruMedix	TTC	
Application No./Patent No.: 6.630,063	Filed/Issue Date: Octob	ber 7, 2003
Entitled: Uniform Laser Excitation and De	ectection in Capillary Arrayelectrophoresis Sy	ystem and Melhod
SpectruMerlix LLC (Name of Assignee)	, 8 <u>limited liability compa</u> (Type of Assignee, e.g., co	any orporation, partnership, university, government egency, etc.)
states that it is:  1.   the assignee of the entire right,	title, and interest; or	
2. an assignee of less than the ent (The extent (by percentage) of it	ire right, title and interest ts ownership interest is%)	
in the patent application/patent identifi	ed above by virtue of either:	
		etified above. The assignment was recorded, Frame, or for which a copy
OR B. A chain of title from the inventor	(s), of the patent application/patent Iden	stified above, to the current assignee as follows:
Reel 010447 , Frame 2. From: SpectruMedix Corpora The document was recor	To: SpectruMedix ded in the United States Patent and Tra e 0368 , or for which a allon	a copy thereof is attached.  LLC ademark Office at
3. From:		
the document was recor	ded in the United States Patent and Tra Frame, or for whi	
✓ Additional documents in the	chain of title are listed on a supplement	al sheet.
As required by 37 CFR 3.73(b)(1 assignee was, or concurrently is being	)(i), the documentary evidence of the ch p, submitted for recordation pursuant to	nain of title from the original owner to the 37 CFR 3.11.
		ument(s)) must be submitted to Assignment t in the records of the USPTO. See MPEP
The undersigned (whose title is suppli	ed below) is authorized to act on behalf	f of the assignee.
Thu h	). Kithox	July 13, 2007
	Signature	Date
	John Ritson	(814) 404-5263
Printed	or Typed Name	Telephone Number
President & C	CEO, SpectruMedix LLC Title	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Qingbo Li, et al.

Art Unit :

1753

Serial No.:

10/679,514

Examiner:

Surekha Vathyam

Filed

October 7, 2003

Ref. No. :

61011-016002

Title

UNIFORM LASER EXCITATION AND DETECTION IN CAPILLARY

ARRAY ELECTROPHORESIS SYSTEM AND METHOD

## STATEMENT UNDER 37 C.F.R. § 3.73(b)

## SUPPLEMENTAL SHEET

Under 37 C.F.R. §3.73(b) SPECTRUMEDIX LLC, a limited liability company, states that it is the Owner of 100% of the entire right, title and interest in U.S. Patent Application No. 10/679,514 identified above by virtue of:

- An Assignment from inventors Qingbo Li, Songsan Zhou, and ChangSheng Liu to SpectruMedix Corporation recorded in the Patent and Trademark Office at Reel 013663, Frame 0939 on October 6, 1999;
- 2. An Assignment from SpectruMedix Corporation to SpectruMedix LLC, recorded in the Patent and Trademark Office at Reel 014465, Frame 0117 on September 8, 2003.

The undersigned, whose title is supplied below, is authorized to act on behalf of the Assignee.

Date: July 12, 2007

President and Chief Executive Officer

SpectruMedix LLC

(814) 404-5263